Stroke is a leading cause of death and disability and new therapies are desperately needed.
Given the complex nature of ischemic brain injury, it has been postulated that cell-based …

Stroke is a leading cause of death and disability and new therapies are desperately needed.
Given the complex nature of ischemic brain injury, it has been postulated that cell-based …

We tested whether stem cells derived from the placenta (human amnion epithelial cells;
hAECs) may represent a novel effective therapy for stroke. Male C57Bl6 mice were …

Ischemic stroke is a crippling disease with few treatment options available. Thus there is an
urgent need for novel therapies that can prevent or reverse the damaging effects of stroke. A …

Stem cells derived from human tissue, including embryonic, induced pluripotent, neural, and
mesenchymal cells, have been reported to rescue injured brain tissue and improve …

Background and Purpose—Human amnion epithelial cells (hAECs) are nonimmunogenic,
nontumorigenic, anti-inflammatory cells normally discarded with placental tissue. We …

Ischemic stroke is a debilitating disease for which there are currently no effective treatments
besides the clot-buster, tissue plasminogen activator (t-PA), which is administered to less …

Background: Stem cells derived from placenta, namely human amnion epithelial cells
(hAECs), possess anti-inflammatory properties and may offer several advantages over other …

Background There is increasing interest in stem cell therapy as another treatment modality
in stroke, particularly for patients who are unable to receive endovascular clot retrieval or …

Background Thrombolytic agents such as tissue plasminogen activator (tPA) are the only
drug class approved to treat ischemic stroke and are usually administered within 4.5 h …